UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

 

 

 

 

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01.   Other Events.

 

On August 25, 2008, Stereotaxis, Inc. (NASDAQ: STXS) (“Stereotaxis” or the “Company”) announced that Biosense Webster, Inc., Stereotaxis’ partner in the development of ablation catheters used with its Niobe Magnetic Navigation System, was notified that it had received CE Mark approval for the commercial sale of the magnetic irrigated catheter in Europe. The Company currently expects that, as a result of this regulatory approval, clinical use of the magnetic irrigated catheter in Europe will take place in the very near term in the context of its partner’s pre launch evaluation. Furthermore, with this approval, the Company expects the magnetic irrigated catheter to be used in Europe for the treatment of complex left sided arrhythmias including atrial fibrillation.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.